MKM Partners Downgrades Alkermes (ALKS) to Neutral
Tweet Send to a FriendGet Alerts ALKS Hot Sheet
Price: $32.84 -0.48%
Rating Summary:
7 Buy, 4 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
7 Buy, 4 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade ALKS Now!
Earlier, MKM Partners downgraded Alkermes (NASDAQ: ALKS) from Buy to Neutral with a price target of $23.00 on valuation.
"While Consta and Sustenna remain strong, Alkermes shares have experienced a significant rally in recent weeks (up 20% since December 31) and are now trading just 2% below our $23 fair value estimate," the analyst notes.
For an analyst ratings summary and ratings history on Alkermes click here. For more ratings news on Alkermes click here.
Shares of Alkermes closed at $22.50 yesterday, with a 52 week range of $14.82-$22.65.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
"While Consta and Sustenna remain strong, Alkermes shares have experienced a significant rally in recent weeks (up 20% since December 31) and are now trading just 2% below our $23 fair value estimate," the analyst notes.
For an analyst ratings summary and ratings history on Alkermes click here. For more ratings news on Alkermes click here.
Shares of Alkermes closed at $22.50 yesterday, with a 52 week range of $14.82-$22.65.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: MKM Partners Downgrades Alkermes (ALKS) to Sell
- Alkermes (ALKS) Smashes Q4 Expectations
- UPDATE: Exane BNP Paribas Downgrades BlackBerry (BBRY) to Underperform; Analyst Says Profit 'Drying Up'
Create E-mail Alert Related Categories
DowngradesLogin with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!

